Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia - PubMed (original) (raw)
Comparative Study
. 2005 May 20;23(15):3433-8.
doi: 10.1200/JCO.2005.04.531. Epub 2005 Apr 4.
Affiliations
- PMID: 15809449
- DOI: 10.1200/JCO.2005.04.531
Comparative Study
Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia
Carol Moreno et al. J Clin Oncol. 2005.
Abstract
Purpose: To investigate whether allogeneic stem-cell transplantation (allo-SCT) may overcome the negative impact of unmutated VH genes in the outcome of patients with chronic lymphocytic leukemia (CLL).
Patients and methods: We analyzed the outcome of patients who underwent SCT according to their VH mutational status.
Results: Thirty-four patients (14 allo-SCT and 20 autologous SCT [auto-SCT]) presented unmutated VH genes and 16 patients presented mutated VH genes (nine allo-SCT and seven auto-SCT). Tumoral burden pre-SCT was significantly higher in the allo-SCT patients independent of the VH mutational status. The risk of relapse was significantly higher after auto-SCT (5-year risk, 61%; 95% CI, 44% to 84%) than after allo-SCT (5-year risk 12%, 95% CI, 3% to 44%; P < .05). In the unmutated group, 13 of 20 auto-SCT and two of 14 allo-SCT patients experienced disease progression, with a risk of relapse at 5 years of 66% (95% CI, 48% to 93%) v 17% (95% CI, 5% to 60%), respectively (P = .01).
Conclusion: These results show that allo-SCT may overcome the unfavorable effect of unmutated VH genes in patients with CLL.
Comment in
- Chronic lymphocytic leukemia: to transplant or not to transplant... that is the question?
Nabhan C, Bitran JD. Nabhan C, et al. J Clin Oncol. 2005 Nov 1;23(31):8126-7; author reply 8127. doi: 10.1200/JCO.2005.03.1690. J Clin Oncol. 2005. PMID: 16258116 No abstract available.
Similar articles
- Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D, García-Marco JA, Martino R, Mateos V, Ribera JM, Sarrá J, León A, Sanz G, de la Serna J, Cabrera R, González M, Sierra J, San Miguel J. Caballero D, et al. Clin Cancer Res. 2005 Nov 1;11(21):7757-63. doi: 10.1158/1078-0432.CCR-05-0941. Clin Cancer Res. 2005. PMID: 16278397 - Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
Muñoz L, Lasa A, Carricondo MT, Hernández C, Ubeda J, Nomdedéu JF. Muñoz L, et al. Cytometry B Clin Cytom. 2007 Mar;72(2):96-102. doi: 10.1002/cyto.b.20149. Cytometry B Clin Cytom. 2007. PMID: 17051526 - VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Aleskog A, Tobin G, Laurell A, Thunberg U, Lindhagen E, Roos G, Nilsson K, Nygren P, Sundström C, Höglund M, Larsson R, Rosenquist R. Aleskog A, et al. Eur J Haematol. 2004 Dec;73(6):407-11. doi: 10.1111/j.1600-0609.2004.00334.x. Eur J Haematol. 2004. PMID: 15522062 - Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.
Kharfan-Dabaja MA, Chavez JC, Khorfan KA, Pinilla-Ibarz J. Kharfan-Dabaja MA, et al. Cancer. 2008 Sep 1;113(5):897-906. doi: 10.1002/cncr.23671. Cancer. 2008. PMID: 18618518 Review. - Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia.
Dreger P, Montserrat E. Dreger P, et al. Leukemia. 2002 Jun;16(6):985-92. doi: 10.1038/sj.leu.2402530. Leukemia. 2002. PMID: 12040430 Review.
Cited by
- Emerging Therapies in CLL in the Era of Precision Medicine.
Iyer P, Wang L. Iyer P, et al. Cancers (Basel). 2023 Mar 3;15(5):1583. doi: 10.3390/cancers15051583. Cancers (Basel). 2023. PMID: 36900373 Free PMC article. Review. - How and when I do allogeneic transplant in CLL.
Gribben JG. Gribben JG. Blood. 2018 Jul 5;132(1):31-39. doi: 10.1182/blood-2018-01-785998. Epub 2018 May 11. Blood. 2018. PMID: 29752258 Free PMC article. Review. - Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.
Shapiro M, Herishanu Y, Katz BZ, Dezorella N, Sun C, Kay S, Polliack A, Avivi I, Wiestner A, Perry C. Shapiro M, et al. Haematologica. 2017 May;102(5):874-882. doi: 10.3324/haematol.2016.148965. Epub 2017 Feb 2. Haematologica. 2017. PMID: 28154084 Free PMC article. - Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland SO, Kröger N. Schetelig J, et al. Bone Marrow Transplant. 2017 Apr;52(4):552-560. doi: 10.1038/bmt.2016.329. Epub 2017 Jan 23. Bone Marrow Transplant. 2017. PMID: 28112746 - Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H; National comprehension cancer network. Zelenetz AD, et al. J Natl Compr Canc Netw. 2015 Mar;13(3):326-62. doi: 10.6004/jnccn.2015.0045. J Natl Compr Canc Netw. 2015. PMID: 25736010 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources